Each of the three companies could have a role to play as the pandemic continues.
ABG has led a $25m investment in Vida Health, an all-in-one virtual care platform managing polychronic physical and behavioural conditions such as diabetes, obesity, hypertension and mental health conditions.
The investment group has also led a $60m investment in Rapid Micro Biosystems, a life science tools company that offers products for the detection and data-tracking of bacterial contamination in the manufacturing of pharmaceuticals, biologics, medical devices, water and food processing, and personal care products.
Finally, it has led an investment of a further $66m in Pulmonx, a medical device company specialising in minimally invasive treatment for patients with severe emphysema.
ABG founder and CEO Frank Yu said: “The Covid-19 pandemic is undoubtedly a watershed event for life science and healthcare around the globe, and further strengthens ABG’s commitment to leading high-impact investments in game-changing innovations in this space.”